MCA Stability Tool

This compatibility recommendation is derived from Adizem-SR and XL 120mg capsules (Napp Pharmaceuticals Ltd), Angitil SR 120 capsules (Ethypharm UK Ltd), Viazem XL 120mg capsules (Thornton & Ross Ltd) and Zemtard 120 XL capsules (Galen Ltd).

Use with caution

Zemtard 180 XL capsules (Galen Ltd)

Explore other Diltiazem formulations Explore other Diltiazem 180mg modified-release capsules suppliers

Stability Notes

Should be stored in airtight, light-resistant containers. Excessive humidity should be avoided.

Provenance

This compatibility recommendation is derived from Adizem-SR and XL 180mg capsules (Napp Pharmaceuticals Ltd), Angitil SR 180 capsules (Ethypharm UK Ltd), Viazem XL 180mg capsules (Thornton & Ross Ltd) and Zemtard 180 XL capsules (Galen Ltd).

Use with caution

Zemtard 240 XL capsules (Galen Ltd)

Explore other Diltiazem formulations Explore other Diltiazem 240mg modified-release capsules suppliers

Stability Notes

Should be stored in airtight, light-resistant containers. Excessive humidity should be avoided.

Provenance

This compatibility recommendation is derived from Adizem-XL 240mg capsules (Napp Pharmaceuticals Ltd), Angitil XL 240 capsules (Ethypharm UK Ltd), Viazem XL 240mg capsules (Thornton & Ross Ltd) and Zemtard 240 XL capsules (Galen Ltd).

Use with caution

Zemtard 300 XL capsules (Galen Ltd)

Explore other Diltiazem formulations Explore other Diltiazem 300mg modified-release capsules suppliers

Stability Notes

Should be stored in airtight, light-resistant containers. Excessive humidity should be avoided.

Provenance

This compatibility recommendation is derived from Adizem-XL 300mg capsules (Napp Pharmaceuticals Ltd), Angitil XL 300 capsules (Ethypharm UK Ltd), Tildiem LA 300, Viazem XL 300mg capsules (Thornton & Ross Ltd) and Zemtard 300 XL capsules (Galen Ltd).

No Stability Information

Zentel 200mg chewable tablets (Imported (Australia))

Explore other Albendazole formulations Explore other Albendazole 200mg chewable tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zentel 400mg chewable tablets (Imported (United States))

Explore other Albendazole formulations Explore other Albendazole 400mg chewable tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zepatier 50mg/100mg tablets (Merck Sharp & Dohme (UK) Ltd)

Explore other Elbasvir + Grazoprevir formulations Explore other Elbasvir 50mg / Grazoprevir 100mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeposia 0.23mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)

Explore other Ozanimod formulations Explore other Ozanimod 230microgram capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeposia 0.23mg/0.46mg capsules treatment initiation pack (Bristol-Myers Squibb Pharmaceuticals Ltd)

Explore other Ozanimod formulations Explore other Ozanimod 230microgram capsules and Ozanimod 460microgram capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeposia 0.46mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)

Explore other Ozanimod formulations Explore other Ozanimod 460microgram capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeposia 0.92mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)

Explore other Ozanimod formulations Explore other Ozanimod 920microgram capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.